Advertisement

Topics

Companies Related to "Aldosterone Blockade Early After Acute Myocardial Infarction" [Most Relevant Company Matches] RSS

15:24 EDT 21st August 2018 | BioPortfolio

Here are the most relevant search results for "Aldosterone Blockade Early After Acute Myocardial Infarction" found in our extensive corporate database of over 50,000 company records.

Showing "Aldosterone Blockade Early After Acute Myocardial Infarction" Companies 1–25 of 1,800+

Extremely Relevant

STENTYS S.A.

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the...


Relevant

Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company’s most advanced drug candidate, AMRS00...

Apogenix GmbH

The biopharmaceutical company Apogenix, located in Heidelberg, Germany, develops innovative drug candidates which exert their therapeutic effect by modulating the programmed cell death (apoptosis). The therapeutic focus lies on acute cerebro- and cardiovascular diseases (e.g. myocardial infarction) where apoptosis is abnormally increased, and on cancer diseases where apoptosis is abnormally decrea...


Lev Pharmaceuticals

We are a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Our product candidates are based on C1-esterase inhibitor (C1-INH), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. We initiated a Phase III clinical trial of our lead product...

t2cure GmbH

t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.

NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (www.neurovive.com) is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome. The research and development program focuses on developing new variants of cyclophilin i...

Labmaster Oy

We focus on delivering innovative diagnostic tools for applications in functional food research and routine clinical diagnostics.The technologies used in products include robust enzyme ligand immunoassay (ELISA), sensitive and robust time-resolved fluorescence immunoassay (TR-FIA) and PCR-based diagnostics. The products are used in functional foods research, routine diagnostics of coeliac diseases...

Blockade Medical

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and neurovascular disease. The company manufactures the Barricade Coil System and is based in Irvine, California.

Blockade Medical LLC

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and related disease of the neurovascular system. The company manufactures the Barricade Coil System in The United States and is based in Irvine, California.

Blockade Medical L.L.C.

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and related disease of the neurovascular system. The company manufactures the Barricade Coil System in The United States and is based in Irvine, California.

Coagulation Diagnostics Incorporated

Coagulation Diagnostics, Inc. (CDI) develops proprietary diagnostic tests for hypercoagulability, or the tendency to form blood clots. The primary applications for the Company's diagnostic tests include monitoring of novel anticoagulants, assessing the risk of acute myocardial infarction, diagnosing possible reactivation of ischemia, and assessing the risk of clotting following invasive cardiovasc...

Stemedica Cell Technologies Inc.

Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clini...

Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that inc...

Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI eve...

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...

DecImmune Therapeutics

DecImmune Therapeutics was founded by Michael Carroll PhD (The Immune Disease Institute, Harvard Medical School), and Francis Moore Jr. MD (Brigham and Women’s Hospital, Harvard Medical School). Drs. Moore and Carroll discovered the epitope of non-muscle myocin heavy chain II (“N2”) that becomes exposed on vascular cells during hypoxia. During ...

Vasomedical, Inc.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic s...

Medivance, Inc.

During the 1990’s, a growing number of animal studies showed evidence that modification of patient temperature could be a critical step in improving patient outcomes after a variety of tragic events, such as stroke, cardiac arrest, and acute myocardial infarction or heart attack. Imprecise and unacceptable methods of controlling patient temperature limited the progression from animal studie...

CardioCell LLC

Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allog...

Pathfinder LLC

Pathfinder is developing a novel cell-based therapy with the potential to revolutionize the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regener...

Selexys Pharmaceuticals Corporation

Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that develops and commercializes therapeutics to treat inflammatory and thrombotic diseases. The company has completed research and is in preclinical development of two drug candidates, a monoclonal antibody and a glycosulfopeptide, that have broad application for the treatment of acute and chronic inflammatory disorders. Th...

Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering...

Maroon Biotech,Corp.

Maroon Biotech has developed a new category of pharmaceuticals called surfactant chaperones. This technology has the capability to restore structure and viabiityto cells disrupted by physical and chemical trauma. By reversing post-traumatic moecular alterations, Maroon Biotech's technology promises to improve recovery from vehicular, military and other types of severe traumatic injuries, electrica...

Ikaria Holdings, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering...

BIOHEART INC.

Bioheart, Inc.Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure (“CHF”) secondary to myocardial infarction (“MI”) and cardiovascular electrical abnormalities. The Company believes that its products hold the potential to revolutionize the treatment of card...


More From BioPortfolio on "Aldosterone Blockade Early After Acute Myocardial Infarction"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks